Suven Life Sciences reveals breakthrough with Ropanicant in depression treatment
Suven Life Sciences Limited has made a significant advancement in the fight against depression, announcing positive results from a Phase-2a proof-of-concept study involving Ropanicant (SUVN-911). The drug, tested for its efficacy in treating moderate to severe Major Depressive Disorder (MDD), showed rapid improvement in depressive symptoms within the first week of treatment. This development marks […]